Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 133, Issue 7
February 14 2019
Issue Cover

Table of Contents

EDITORIAL

Introduction to a review series on advances in multiple myeloma
Hervé Avet-Loiseau
View Articletitled, Introduction to a review series on advances in multiple myeloma

BLOOD COMMENTARIES

PLATELETS AND THROMBOPOIESIS
Megakaryocytes from fat: a new recipe for platelets
Alessandra Balduini
View Articletitled, Megakaryocytes from fat: a new recipe for platelets
CLINICAL TRIALS AND OBSERVATIONS
IDH2 inhibition: another piece to the puzzle
Clinical Trials & Observations
Lars Bullinger
View Articletitled, IDH2 inhibition: another piece to the puzzle
Lymphoid Neoplasia
Off-target effects of carfilzomib that cause cardiotoxicity
Jan S. Moreb
View Articletitled, Off-target effects of carfilzomib that cause cardiotoxicity
Lymphoid Neoplasia
Yet another susceptibility variant for ALL: what’s next?
Kjeld Schmiegelow
View Articletitled, Yet another susceptibility variant for ALL: what’s next?
PLATELETS AND THROMBOPOIESIS
More than one pathway: novel treatment for ITP
Cindy E. Neunert,Michele P. Lambert
View Articletitled, More than one pathway: novel treatment for ITP
THROMBOSIS AND HEMOSTASIS
Hepatocyte tPA: where have you been hiding?
Steven L. Gonias
View Articletitled, Hepatocyte tPA: where have you been hiding?

PLENARY PAPER

PLATELETS AND THROMBOPOIESIS
Megakaryocytes and platelets from a novel human adipose tissue–derived mesenchymal stem cell line
Keiichi Tozawa,Yukako Ono-Uruga,Masaki Yazawa,Taisuke Mori,Mitsuru Murata,Shinichiro Okamoto,Yasuo Ikeda,Yumiko Matsubara
View Articletitled, Megakaryocytes and platelets from a novel human adipose tissue–derived mesenchymal stem cell line
Supplemental data

REVIEW SERIES

Imaging in multiple myeloma: How? When?
Clinical Trials & Observations
Elena Zamagni,Paola Tacchetti,Michele Cavo
View Articletitled, Imaging in multiple myeloma: How? When?
Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing
Clinical Trials & Observations
Shaji K. Kumar,Francis K. Buadi,S. Vincent Rajkumar
View Articletitled, Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing
Toward personalized treatment in multiple myeloma based on molecular characteristics
Clinical Trials & Observations
Charlotte Pawlyn,Faith E. Davies
View Articletitled, Toward personalized treatment in multiple myeloma based on molecular characteristics

CLINICAL TRIALS AND OBSERVATIONS

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib
Clinical Trials & Observations
Eytan M. Stein,Courtney D. DiNardo,Amir T. Fathi,Daniel A. Pollyea,Richard M. Stone,Jessica K. Altman,Gail J. Roboz,Manish R. Patel,Robert Collins,Ian W. Flinn,Mikkael A. Sekeres,Anthony S. Stein,Hagop M. Kantarjian,Ross L. Levine,Paresh Vyas,Kyle J. MacBeth,Alessandra Tosolini,Jason VanOostendorp,Qiang Xu,Ira Gupta,Thomas Lila,Alberto Risueno,Katharine E. Yen,Bin Wu,Eyal C. Attar,Martin S. Tallman,Stéphane de Botton
View Articletitled, Molecular remission and response patterns in patients with mutant-<em>IDH2</em> acute myeloid leukemia treated with enasidenib
Supplemental data

HEMATOPOIESIS AND STEM CELLS

Serial transplantation reveals a critical role for endoglin in hematopoietic stem cell quiescence
Luciene Borges,Vanessa K. P. Oliveira,June Baik,Sean C. Bendall,Rita C. R. Perlingeiro
View Articletitled, Serial transplantation reveals a critical role for endoglin in hematopoietic stem cell quiescence
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
Rosalie M. Sterner,Reona Sakemura,Michelle J. Cox,Nan Yang,Roman H. Khadka,Cynthia L. Forsman,Michael J. Hansen,Fang Jin,Katayoun Ayasoufi,Mehrdad Hefazi,Kendall J. Schick,Denise K. Walters,Omar Ahmed,Dale Chappell,Tarek Sahmoud,Cameron Durrant,Wendy K. Nevala,Mrinal M. Patnaik,Larry R. Pease,Karen E. Hedin,Neil E. Kay,Aaron J. Johnson,Saad S. Kenderian
View Articletitled, GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
Supplemental data

LYMPHOID NEOPLASIA

Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin
Panagiotis Efentakis,Georgios Kremastiotis,Aimilia Varela,Panagiota-Efstathia Nikolaou,Eleni-Dimitra Papanagnou,Constantinos H. Davos,Maria Tsoumani,Georgios Agrogiannis,Anastasia Konstantinidou,Efstathios Kastritis,Zoi Kanaki,Efstathios K. Iliodromitis,Apostolos Klinakis,Meletios A. Dimopoulos,Ioannis P. Trougakos,Ioanna Andreadou,Evangelos Terpos
View Articletitled, Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin
Supplemental data
Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics
Brief Report
Maoxiang Qian,Heng Xu,Virginia Perez-Andreu,Kathryn G. Roberts,Hui Zhang,Wenjian Yang,Shouyue Zhang,Xujie Zhao,Colton Smith,Meenakshi Devidas,Julie M. Gastier-Foster,Elizabeth Raetz,Eric Larsen,Esteban G. Burchard,Naomi Winick,W. Paul Bowman,Paul L. Martin,Michael Borowitz,Brent Wood,Federico Antillon-Klussmann,Ching-Hon Pui,Charles G. Mullighan,William E. Evans,Stephen P. Hunger,Mary V. Relling,Mignon L. Loh,Jun J. Yang
View Articletitled, Novel susceptibility variants at the <em>ERG</em> locus for childhood acute lymphoblastic leukemia in Hispanics
Supplemental data

PLATELETS AND THROMBOPOIESIS

Low-dose chidamide restores immune tolerance in ITP in mice and humans
Hong-yu Zhao,Ya-hui Ma,Da-qi Li,Tao Sun,Li-zhen Li,Ping Li,Xin-guang Liu,Hai Zhou,Yu Hou,Yang Liu,Pan-pan Han,Ya-jing Zhao,Fang-miao Jing,Jun Peng,Ming Hou
View Articletitled, Low-dose chidamide restores immune tolerance in ITP in mice and humans
Supplemental data

THROMBOSIS AND HEMOSTASIS

An ATF6-tPA pathway in hepatocytes contributes to systemic fibrinolysis and is repressed by DACH1
Ze Zheng,Lalitha Nayak,Wei Wang,Arif Yurdagul, Jr,Xiaobo Wang,Bishuang Cai,Stephanie Lapping,Lale Ozcan,Rajasekhar Ramakrishnan,Richard G. Pestell,Mukesh K. Jain,Ira Tabas
View Articletitled, An ATF6-tPA pathway in hepatocytes contributes to systemic fibrinolysis and is repressed by DACH1
Supplemental data

TRANSPLANTATION

The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases
Clinical Trials & Observations
Monica S. Thakar,Larisa Broglie,Brent Logan,Andrew Artz,Nancy Bunin,Lauri M. Burroughs,Caitrin Fretham,David A. Jacobsohn,Alison W. Loren,Joanne Kurtzberg,Caridad A. Martinez,Shin Mineishi,Adam S. Nelson,Ann Woolfrey,Marcelo C. Pasquini,Mohamed L. Sorror
View Articletitled, The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases
Supplemental data

LETTER TO BLOOD

Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay
Clinical Trials & Observations
Eli Muchtar,Shaji K. Kumar,Morie A. Gertz,Martha Grogan,Omar F. AbouEzzeddine,Allan S. Jaffe,Angela Dispenzieri
View Articletitled, Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay
Supplemental data

BLOOD WORK

Intraocular toxoplasmosis mimicking vitreous lymphoma
Ruijun Jeanna Su,Jonathan Said
View Articletitled, Intraocular toxoplasmosis mimicking vitreous lymphoma

ERRATUM

Porpaczy E, Tripolt S, Hoelbl-Kovacic A, et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood. 2018;132(7):694-706.
View Articletitled, Porpaczy E, Tripolt S, Hoelbl-Kovacic A, et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. <em>Blood.</em> 2018;132(7):694-706.
  • Cover Image

    Cover Image

    issue cover

    Illustration based on brain magnetic resonance imaging (MRI) of an acute lymphoblastic leukemia patient–derived xenograft treated with CD19-directed chimeric antigen receptor T-cell (CART19) therapy and granulocyte-macrophage colony-stimulating factor (GM-CSF)–neutralizing antibodies. GM-CSF depletion during CART19 therapy results in reduced neuroinflammation. See the article by Sterner et al on page 697.

  • PDF Icon PDF LinkFront Matter
  • PDF Icon PDF LinkTable of Contents
  • PDF Icon PDF LinkBack Matter
  • PDF Icon PDF LinkEditorial Board
All Issues

Advertisement intended for health care professionals

For how long has this problem been there?
Targeting CD47: many misses; hopeful for a hit
Woyach JA, Burbano GP, Ruppert AS, et al. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood. 2024;143(16):1616-1627.
MRD-guided zanubrutinib, venetoclax and obinutuzumab in relapsed CLL: primary endpoint analysis from the CLL2-BZAG trial
Sickle Cell Trait Does Not Cause "Sickle Cell Crisis" Leading to Exertion-Related Death: A Systematic Review

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals